Gonadotropin-resistant ovary syndrome
Gonadotropin-resistant Ovary Syndrome
Gonadotropin-resistant ovary syndrome (GROS), also known as Savage syndrome, is a rare condition characterized by the failure of the ovaries to respond to gonadotropin stimulation. This condition leads to primary ovarian insufficiency, resulting in amenorrhea and infertility in affected women.
Pathophysiology[edit | edit source]
GROS is primarily caused by a defect in the ovarian receptors for gonadotropins, specifically the follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are crucial for the normal development and function of the ovaries. In GROS, despite normal or elevated levels of circulating gonadotropins, the ovaries fail to respond, leading to anovulation and estrogen deficiency.
Clinical Presentation[edit | edit source]
Women with gonadotropin-resistant ovary syndrome typically present with:
- Primary or secondary amenorrhea
- Infertility
- Symptoms of estrogen deficiency, such as hot flashes and vaginal dryness
Diagnosis[edit | edit source]
The diagnosis of GROS is made based on clinical presentation, laboratory findings, and exclusion of other causes of ovarian insufficiency. Key diagnostic criteria include:
- Elevated serum gonadotropin levels (FSH and LH)
- Low serum estradiol levels
- Normal karyotype (46,XX)
- Exclusion of autoimmune and genetic causes of ovarian failure
Treatment[edit | edit source]
Management of GROS focuses on addressing the symptoms of estrogen deficiency and infertility. Treatment options include:
- Hormone replacement therapy (HRT) to alleviate symptoms of estrogen deficiency
- Assisted reproductive technologies (ART) such as in vitro fertilization (IVF) with donor oocytes for women desiring pregnancy
Prognosis[edit | edit source]
The prognosis for women with GROS in terms of fertility is generally poor without the use of donor oocytes. However, hormone replacement therapy can effectively manage symptoms of estrogen deficiency and improve quality of life.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD, Dr.T
